5PSQ-063 Response to abiraterone and enzalutamide in castrate-resistant prostate cancer in clinical practice

BACKGROUND: Abiraterone and enzalutamide are recommended for patients with metastatic castrate-resistant prostate cancer (mCRPC) who are chemotherapy-naive or have received treatment with docetaxel. Clinical practice guidelines do not explain the optimal sequence or combination of these agents. Sequ...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Eur J Hosp Pharm
Main Authors: Ortega, P Ranz, Fernández, R Díez, García, TMolina
Format: Artigo
Sprog:Inglês
Udgivet: BMJ Group 2018
Fag:
Section 5: Patient safety and quality assurance
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535567/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.417
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker